138 related articles for article (PubMed ID: 35235893)
1. PET-CT staging affects time to treatment in sarcoma.
Lee L; Kazmer A; Colman MW; Gitelis S; Batus M; Blank AT
Surg Oncol; 2022 May; 41():101732. PubMed ID: 35235893
[TBL] [Abstract][Full Text] [Related]
2. What is the clinical impact of staging and surveillance PET-CT scan findings in patients with bone and soft tissue sarcoma?
Lee L; Kazmer A; Colman MW; Gitelis S; Batus M; Blank AT
J Surg Oncol; 2022 Apr; 125(5):901-906. PubMed ID: 35023167
[TBL] [Abstract][Full Text] [Related]
3. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
4. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
[TBL] [Abstract][Full Text] [Related]
5. The impact of
Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
[TBL] [Abstract][Full Text] [Related]
7. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
Peterson JJ
Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
[TBL] [Abstract][Full Text] [Related]
8. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas.
Piperkova E; Mikhaeil M; Mousavi A; Libes R; Viejo-Rullan F; Lin H; Rosen G; Abdel-Dayem H
Clin Nucl Med; 2009 Mar; 34(3):146-50. PubMed ID: 19352275
[TBL] [Abstract][Full Text] [Related]
9. FDG PET/MR in initial staging of sarcoma: Initial experience and comparison with conventional imaging.
Platzek I; Beuthien-Baumann B; Schramm G; Maus J; Laniado M; Kotzerke J; van den Hoff J; Schuler M
Clin Imaging; 2017; 42():126-132. PubMed ID: 27951459
[TBL] [Abstract][Full Text] [Related]
10. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
[TBL] [Abstract][Full Text] [Related]
11. Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas.
Rakheja R; Makis W; Tulbah R; Skamene S; Holcroft C; Nahal A; Turcotte R; Hickeson M
AJR Am J Roentgenol; 2013 Jul; 201(1):170-7. PubMed ID: 23789672
[TBL] [Abstract][Full Text] [Related]
12. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging.
Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Kim EE
Radiology; 2007 Dec; 245(3):839-47. PubMed ID: 18024454
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
[TBL] [Abstract][Full Text] [Related]
14. Role of
Mercolini F; Zucchetta P; Jehanno N; Corradini N; Van Rijn RR; Rogers T; Cameron A; Scarzello G; Coppadoro B; Minard-Colin V; Gallego S; Chisholm J; Merks JH; Bisogno G
Eur J Cancer; 2021 Sep; 155():155-162. PubMed ID: 34385068
[TBL] [Abstract][Full Text] [Related]
15. Functional image in soft tissue sarcomas: An update of the indications of
Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457
[TBL] [Abstract][Full Text] [Related]
16. PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma.
Kandathil A; Subramaniam RM
PET Clin; 2017 Oct; 12(4):475-488. PubMed ID: 28867117
[TBL] [Abstract][Full Text] [Related]
17. What Is the Clinical Importance of Incidental Findings on Staging CT Scans in Patients With Sarcoma?
Mayo Z; Kennedy S; Gao Y; Miller BJ
Clin Orthop Relat Res; 2019 Apr; 477(4):730-737. PubMed ID: 30601764
[TBL] [Abstract][Full Text] [Related]
18. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?
Walter F; Czernin J; Hall T; Allen-Auerbach M; Walter MA; Dunkelmann S; Federman N
J Pediatr Hematol Oncol; 2012 Mar; 34(2):131-6. PubMed ID: 22134608
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of
Kassem TW; Abdelaziz O; Emad-Eldin S
Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778
[TBL] [Abstract][Full Text] [Related]
20. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Musculoskeletal Cancers.
Broski SM
PET Clin; 2024 Apr; 19(2):217-229. PubMed ID: 38184453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
